DIAGNOS Announces an Extension to the Diabetic Retinopathy Screening Services Assisted by Artificial Intelligence (AI) at the...
September 03 2019 - 11:28AM
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK)
(OTCQB: DGNOF) a leader in early detection of critical health
issues through the use of its FL
AIRE platform
based on Artificial Intelligence (
AI), announces
today the extension of the automated detection of Diabetic
Retinopathy at the CHUM (Centre hospitalier de l’Université de
Montréal) until the end of 2019.
Technological showcaseLaunched
in June 2018 in collaboration with the ophthalmology and
endocrinology department, the technology showcase has allowed more
than a thousand patients from the CHUM to access screening
technology. DIAGNOS will continue to be present at the CHUM until
the end of 2019 to test the latest algorithms being released for
full automated environment.
“This technological showcase is very important
to us. We have been able to demonstrate it’s capability and
save vision of patients. We continue to demonstrate our
expertise to our future Canadian and international clients. We can
present the precision of our algorithms in the detection and
classification of the patients in order of the severity of the
disease. The CHUM is now showing us how they use our
technology in their operations and we are learning from them while
improving our offering, said Yves-Stephane Couture, Vice President
at DIAGNOS.
DIAGNOS has screened to date more than 300,000
diabetic patients. Thanks to the support of the Government of
Quebec and our collaboration with the CHUM, this technological
showcase keeps helping DIAGNOS to demonstrate our expertise in the
province. We strongly believe this project will also help set up
extensive screening campaigns in other Canadian provinces and in
the United States.
About DIAGNOSDIAGNOS is a publicly-traded
Canadian corporation with a mission of early detection of critical
health issues through the use of its Artificial Intelligence (“AI”)
tool CARA (Computer Assisted Retina Analysis). CARA is a
tele-ophthalmology platform that integrates with existing equipment
(hardware and software) and processes at the point of care. CARA’s
Artificial Intelligence image enhancement algorithms make standard
retinal images sharper, clearer and easier to read. CARA is
accessible securely over the internet, and is compatible with all
recognized image formats and brands of fundus cameras, and is EMR
compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time. CARA complies with local
regulations, is FDA cleared for commercialization in the United
States of America is Health Canada licensed for commercialization
in Canada and is CE marking compliant in Europe.
Additional information is available at
www.diagnos.com and www.sedar.com
For further information, please contact:
Mr. André Larente, PresidentDIAGNOS Inc.Tel:
450-678-8882 ext. 224alarente@diagnos.ca
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publically update or revise any forward-looking information,
whether as a result of new information, future events or otherwise.
The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024